Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.

Abstract

Antisense oligonucleotides have been used to suppress the expression of a number of oncogenes and growth factors (7-9). Point mutations represent a well-defined target for antisense oligonucleotides. We (10) and others (11,12)

A Long-Life, High-Rate Lithium/Sulfur Cell: A Multifaceted Approach to Enhancing Cell Performance

“…In this work, we used CTAB-modified S−GO nanocomposite to address this issue. CTAB is one kind of cationic surfactant (Scheme S1) used to modify the surface functionality of nanoparticles (e.g., iron oxides) in drug delivery 31,32 and water treatment. 33−35 It is well-known that the amount of CTAB can significantly affect the adsorption capability toward dyes and organic compounds when deposited onto the surface of these nanoparticles.…”

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

“…Interestingly, the oligonucleotides-CTAB complex alone exerted no effect on HBL1000ras1 cell proliferation. Analysis of the amount of intact intracellular oligonucleotides, in cell culture experiments, revealed concentrations 100-fold higher in cells treated with oligonucleotides-CTAB adsorbed onto nanospheres [129].…”

SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression

“…Because the evidence is becoming stronger for the non-sequencespecific effects of phosphorothioate ODN (Stein and Cheng, 1993;Gura, 1995;Stein, 1995), the development of ODN carriers would seem necessary to improve both the transport and the stability of native ODNs, while preserving their target specificity. Synthetic commercialized cationic lipids, such as DOTMA or DOTAP (Capaccioli et al, 1993;Dean and Mckay, 1994), or synthetic carriers such as nanoparticles (Schwab et al, 1994) are widely used because of their efficiency in enhancing antisense ODN uptake into cells and decreasing their degradation. These ODN carriers are promising for in vitro experiments and local administration, but their instability and the cellular toxicity of these complexes limit their use for in vivo systemic administration (Lewis et al, 1996).…”